Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330453 | 0.90 | SLC6A4 (0.36) | KDM1ASLC6A4SLC6A3 | |
| SCHEMBL20322411 | 0.86 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL21933931 | 0.86 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL22661467 | 0.85 | HRH3 (0.34) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20128711 | 0.83 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL20328693 | 0.82 | ALDH1A1 (0.47) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL24079489 | 0.81 | KDM4E (0.32) | KDM4EALDH1A1SMN1; SMN2HTTHTR1A | |
| SCHEMBL21125082 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL21933939 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL24079510 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KDM4E 1205/4885ALDH1A1 3688/4885SMN1; SMN2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.